$PRAX
Praxis Precision Medicines, Inc. Stock $prax

$prax Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000168954822000014 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.15M	$11.63M	$47.08M
YoY Change	60.44%	239.18%	177.07%
% of Gross Profit
Research & Development	$43.51M	$33.14M	$120.3M
YoY Change	167.43%	159.18%	167.38%
% of Gross Profit
Depreciation & Amortization	$93.00K	$39.00K	$182.0K
YoY Change	365.0%	290.0%	264.0%
% of Gross Profit
Operating Expenses	$58.66M	$44.77M	$167.3M
YoY Change	128.15%	176.09%	170.03%
Operating Profit		-$44.77M	-$167.3M
YoY Change		176.09%	170.03%
Interest Expense	$70.00K	$73.00K	$271.0K
YoY Change	600.0%		93.57%
% of Operating Profit
Other Income/Expense, Net		$73.00K	$271.0K
YoY Change		7200.0%	93.57%
Pretax Income	-$58.59M	-$44.70M	-$167.1M
YoY Change	127.88%	175.65%	170.2%
Income Tax	-$5.000K	$5.000K	$0.00
% Of Pretax Income
Net Earnings	-$58.58M	-$44.71M	-$167.1M
YoY Change	127.89%	175.68%	170.24%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.00	-$3.94
Diluted Earnings Per Share	-$1.302M	-$1.00	-$3.94
COMMON SHARES
Basic Shares Outstanding	44.86M shares	44.71M shares	42.45M shares
Diluted Shares Outstanding		44.71M shares	42.45M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$244.4M	$277.9M	$275.9M
YoY Change	-17.61%	142.05%	-6.98%
Cash & Equivalents	$138.7M	$165.7M	$138.7M
Short-Term Investments	$105.7M	$112.2M	$137.2M
Other Short-Term Assets	$11.50M	$4.969M	$11.50M
YoY Change	101.72%	351.73%	101.72%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$287.4M	$319.3M	$287.4M
YoY Change	-4.93%	175.65%	-4.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.213M	$625.0K	$4.866M
YoY Change	1379.27%	537.76%	508.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$472.0K	$416.0K	$472.0K
YoY Change	3046.67%	-79.86%
Total Long-Term Assets	$5.338M	$5.069M	$5.338M
YoY Change	527.26%	37.11%	493.11%
TOTAL ASSETS
Total Short-Term Assets	$287.4M	$319.3M	$287.4M
Total Long-Term Assets	$5.338M	$5.069M	$5.338M
Total Assets	$292.7M	$324.4M	$292.7M
YoY Change	-3.44%	171.36%	-3.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.78M	$7.544M	$10.78M
YoY Change	163.7%	118.54%	162.93%
Accrued Expenses	$26.84M	$16.53M	$27.65M
YoY Change	146.98%	167.2%	138.4%
Deferred Revenue	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$38.43M	$24.75M	$38.43M
YoY Change	144.49%	138.39%	144.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.501M	$3.732M	$3.501M
YoY Change		1766.0%
Total Long-Term Liabilities	$3.501M	$3.732M	$3.501M
YoY Change		1766.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.43M	$24.75M	$38.43M
Total Long-Term Liabilities	$3.501M	$3.732M	$3.501M
Total Liabilities	$41.94M	$28.49M	$41.94M
YoY Change	166.76%	169.19%	167.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$316.6M	-$258.0M
YoY Change	111.71%	109.31%
Common Stock	$5.000K	$5.000K
YoY Change	25.0%	400.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	0.000 shares	0.000 shares
Shareholders Equity	$250.8M	$295.9M	$250.8M
YoY Change
Total Liabilities & Shareholders Equity	$292.7M	$324.4M	$292.7M
YoY Change	-3.44%	171.36%	-3.45%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021
OPERATING ACTIVITIES
Net Income	-$58.58M	-$44.71M	-$167.1M
YoY Change	127.89%	175.68%	170.24%
Depreciation, Depletion And Amortization	$93.00K	$39.00K	$182.0K
YoY Change	365.0%	290.0%	264.0%
Cash From Operating Activities	-$44.86M	-$23.96M	-$124.6M
YoY Change	121.84%	72.51%	136.69%
INVESTING ACTIVITIES
Capital Expenditures	-$531.0K	-$450.0K	$1.050M
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$10.70M	$14.00M	-$139.5M
YoY Change
Cash From Investing Activities	$10.17M	$13.55M	-$140.5M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$98.41M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.713M	212.0K	$107.6M
YoY Change	-96.18%	-99.81%	-64.66%
NET CHANGE
Cash From Operating Activities	-44.86M	-23.96M	-$124.6M
Cash From Investing Activities	10.17M	13.55M	-$140.5M
Cash From Financing Activities	7.713M	212.0K	$107.6M
Net Change In Cash	-26.98M	-10.20M	-$157.5M
YoY Change	-114.83%	-110.74%	-162.55%
FREE CASH FLOW
Cash From Operating Activities	-$44.86M	-$23.96M	-$124.6M
Capital Expenditures	-$531.0K	-$450.0K	$1.050M
Free Cash Flow	-$44.33M	-$23.51M	-$125.6M
YoY Change	119.22%	69.27%	138.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001689548
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-39620
CY2021	dei	Entity Registrant Name EntityRegistrantName	PRAXIS PRECISION MEDICINES, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5195942
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	99 High Street
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	30th Floor
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02110
CY2021	dei	City Area Code CityAreaCode	617
CY2021	dei	Local Phone Number LocalPhoneNumber	300-8460
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2021	dei	Trading Symbol TradingSymbol	PRAX
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	761000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45487614	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	138704000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	296608000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	137207000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11498000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5718000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	287409000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	302326000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1213000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	82000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3653000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	754000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	472000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15000	USD
CY2021Q4	us-gaap	Assets Assets	292747000	USD
CY2020Q4	us-gaap	Assets Assets	303177000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10780000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4088000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	26844000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10869000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	810000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	763000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38434000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15720000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3501000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Liabilities Liabilities	41935000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	15720000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45300514	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45300514	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38268543	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38268543	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	567598000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	437007000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-176000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-316615000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-149554000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	250812000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	287457000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	292747000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	303177000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	120257000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44976000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47075000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16992000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	167332000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	61968000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-167332000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-61968000	USD
CY2021	us-gaap	Interest Income Other InterestIncomeOther	271000	USD
CY2020	us-gaap	Interest Income Other InterestIncomeOther	140000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	271000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	140000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-167061000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61828000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167061000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-61820000	USD
CY2021	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	0	USD
CY2020	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	8996000	USD
CY2021	prax	Gain Loss On Repurchase Of Temporary Equity GainLossOnRepurchaseOfTemporaryEquity	0	USD
CY2020	prax	Gain Loss On Repurchase Of Temporary Equity GainLossOnRepurchaseOfTemporaryEquity	493000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-167061000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-70323000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.94
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.94
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.86
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.86
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42454055	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42454055	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8950152	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8950152	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167061000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-61820000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-176000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-167237000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61820000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	287457000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4666000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	851000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-86000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-27373000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	265515000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5400000	USD
CY2021Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	229000	USD
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	98413000	shares
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	809000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	36000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-36401000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	333772000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6521000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	309000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	25000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-44705000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	295922000	USD
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6106000	USD
CY2021Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	598000	USD
CY2021Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	478000	USD
CY2021Q4	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-151000	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-58582000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	250812000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-81008000	USD
CY2020Q1	prax	Temporary Equity Issuance Costs TemporaryEquityIssuanceCosts	37000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	147000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	2064000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-8330000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-90762000	USD
CY2020Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	285000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	2039000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-11568000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-104084000	USD
CY2020Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	154000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	953000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	3943000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-16216000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-123263000	USD
CY2020Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2864000	USD
CY2020Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	200311000	shares
CY2020Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3826000	USD
CY2020Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	61000	USD
CY2020Q4	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	950000	USD
CY2020Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	233178000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-25706000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	287457000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167061000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-61820000	USD
CY2021	us-gaap	Depreciation Depreciation	182000	USD
CY2020	us-gaap	Depreciation Depreciation	50000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	22693000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5211000	USD
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1412000	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	696000	USD
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2087000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5780000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4437000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7267000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	960000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	15450000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7408000	USD
CY2021	prax	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-763000	USD
CY2020	prax	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-696000	USD
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-41000	USD
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	5000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-124554000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52623000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1050000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	164170000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	24700000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-140520000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2021	prax	Proceeds From At The Market Offerings Net Of Issuance Costs ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts	7301000	USD
CY2020	prax	Proceeds From At The Market Offerings Net Of Issuance Costs ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	98413000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	200886000	USD
CY2021	prax	Payments Of Stock Issuance Costs Related To Ipo PaymentsOfStockIssuanceCostsRelatedToIPO	575000	USD
CY2020	prax	Payments Of Stock Issuance Costs Related To Ipo PaymentsOfStockIssuanceCostsRelatedToIPO	0	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2447000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	88000	USD
CY2021	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	133442000	USD
CY2021	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock	0	USD
CY2020	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock	30000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	107586000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	304416000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-157488000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	251793000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	297208000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45415000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139720000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	297208000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	138704000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	296608000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1016000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	600000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139720000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	297208000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4086000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021	prax	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	262000	USD
CY2020	prax	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	575000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	267000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4000	USD
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	8996000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Nature of the Business<div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and disease. The Company is applying insights from genetic epilepsies to both rare and more prevalent neurological and psychiatric disorders, using its understanding of shared biological targets and circuits in the brain. The Company applies a deliberate and pragmatic precision approach, leveraging a suite of translational tools including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, the Company has established a broad CNS portfolio with multiple programs, including product candidates across psychiatric disorders, movement disorders, epilepsy and other exploratory CNS indications, with three clinical-stage product candidates. Each of the Company's clinical-stage product candidates is advancing in more than one indication and the Company anticipates expansion into additional indications. The Company expects multiple topline readouts from its clinical-stage programs and anticipates the launch of a fourth clinical development program in 2022. In addition, the Company has established a robust pipeline of preclinical stage programs through internal research and in-licensing.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's broad portfolio of CNS programs is currently structured by therapeutic focus in three primary franchises – Psychiatry, Movement Disorders and Epilepsy. In addition, the Company is pursuing development in other exploratory CNS indications such as rare adult cephalgias. Within the Psychiatry franchise, the Company's most advanced clinical candidate, PRAX-114, is being developed for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder, or PTSD. In addition, the Company has initiated a Phase 2, placebo-controlled study evaluating PRAX-114 for the treatment of PTSD. Within the Movement Disorders franchise, the Company's second clinical candidate, PRAX-944, is being developed for the treatment of Essential Tremor, or ET, and Parkinson's Disease, or PD. The Company has initiated a Phase 2b placebo-controlled dose-range finding trial, the Essential1 Study, to evaluate the tolerability, safety and efficacy of PRAX-944 in adults with ET. The Company also expects to initiate a Phase 2, placebo-controlled, crossover study to evaluate the safety, pharmacokinetics, or PK, and efficacy of daytime dosing of PRAX-114 for the treatment of ET in the first quarter of 2022. The Company expects to initiate a Phase 2, placebo-controlled trial to evaluate the safety, PK and efficacy of PRAX-944 as a non-dopaminergic treatment for the motor symptoms of PD in the second quarter of 2022. Within the Epilepsy franchise, the Company expects to initiate a Phase 2 study with its third clinical-stage candidate, PRAX-562, in the second quarter of 2022 in patients with rare pediatric Developmental and Epileptic Encephalopathies. The Company's most advanced preclinical stage product candidate within its Epilepsy franchise, PRAX-222, is an antisense oligonucleotide, or ASO, designed to decrease the expression levels of the protein encoded by the gene SCN2A in patients with gain-of-function SCN2A mutations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to initiate a seamless study of PRAX-222 in the second quarter of 2022, which would be its fourth program to reach clinical stage. The Company also expects to initiate a Phase 2 proof-of-concept clinical trial evaluating PRAX-562 in patients with rare adult cephalgias in the first quarter of 2022. In addition, the Company's preclinical pipeline consists of a discovery program in development for KCNT1 related epilepsy, PRAX-628, a product candidate nominated in the fourth quarter of 2021 for focal epilepsy, three ASOs targeting SCN2A in patients with loss-of-function mutations, PCDH19 and SYNGAP1, respectively, and three additional discovery programs for undisclosed targets in psychiatry, movement disorders and epilepsy. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Praxis was incorporated in 2015 and commenced operations in 2016. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock, and from the sale of common stock through an initial public offering ("IPO"), a follow-on public offering and at-the-market offerings under its shelf registration statement. From inception through December 31, 2021, the Company raised $516.4 million in aggregate cash proceeds from these transactions, net of issuance costs.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Update ("ASU") 2014-15, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses since its inception, including a net loss of $167.1 million for the year ended December 31, 2021. In addition, as of December 31, 2021, the Company had an accumulated deficit of $316.6 million. The Company expects to continue to generate operating losses for the foreseeable future. </span></div>The Company expects that its cash, cash equivalents and marketable securities as of December 31, 2021 of $275.9 million will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company's inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.
CY2021	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	516400000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167100000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-316600000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	275900000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, accrued and prepaid research and development expenses, stock-based compensation expense and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	138704000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	296608000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1016000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	600000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139720000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	297208000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Significant Suppliers and License Agreements</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company's investment portfolio comprises money market funds, marketable debt securities, including debt securities issued by U.S. government agencies and </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corporations, and commercial paper. The Company investments are limited to investment-grade securities with strong credit ratings with the objective of maintaining safety and liquidity. The Company also maintains deposits in accredited financial institutions in excess of federally insured limits. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (the “FDIC”) up to $250,000. As of December 31, 2021 and 2020, the Company’s primary operating accounts significantly exceeded the FDIC limits. The Company deposits its cash in financial institutions that it believes have high credit quality, and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on third-party manufacturers to supply materials for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies, and expects to continue to rely, on a small number of third-party manufacturers to produce and process its current and potential product candidates and to manufacture supply of its current and potential product candidates for preclinical and clinical activities. These programs could be adversely affected by a significant interruption in the supply of the necessary materials. The Company is also dependent on third parties who provide license rights used in the development of certain programs. The Company could experience delays in the development of its programs if any of these license agreements are terminated, if the Company fails to meet the obligations required under its arrangements, or if the Company is unable to successfully secure new strategic alliances or licensing agreements.</span></div>
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	25067977	shares
CY2021	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	0	USD
CY2020	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	0	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	600000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	600000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	600000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	600000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	31529000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	137383000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	177000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	105716000	USD
CY2021Q4	prax	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax	1000	USD
CY2021Q4	prax	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax	39000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	105678000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	31667000	USD
CY2021Q4	prax	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Noncurrent Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax	0	USD
CY2021Q4	prax	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Noncurrent Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax	138000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	137207000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	14	program
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	95800000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1366000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	170000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	153000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	88000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1213000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	82000	USD
CY2021Q4	prax	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	17763000	USD
CY2020Q4	prax	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	4206000	USD
CY2021Q4	prax	Accrued Personnel Related Expenses Current AccruedPersonnelRelatedExpensesCurrent	7180000	USD
CY2020Q4	prax	Accrued Personnel Related Expenses Current AccruedPersonnelRelatedExpensesCurrent	5516000	USD
CY2021Q4	prax	Accrued License Fees Current AccruedLicenseFeesCurrent	1539000	USD
CY2020Q4	prax	Accrued License Fees Current AccruedLicenseFeesCurrent	133000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	362000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1014000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	26844000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10869000	USD
CY2021Q4	prax	Percentage Increase In Annual Base Rent PercentageIncreaseInAnnualBaseRent	0.02
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4100000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4100000	USD
CY2018Q4	prax	Percentage Increase In Annual Base Rent PercentageIncreaseInAnnualBaseRent	0.01
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4311000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	763000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	763000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3501000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3653000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	754000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	810000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1412000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	782000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	110000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5157000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	34000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	14000	USD
CY2021	us-gaap	Lease Cost LeaseCost	1446000	USD
CY2020	us-gaap	Lease Cost LeaseCost	796000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1160000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1270000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1296000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1321000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	846000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4311000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	53644314	shares
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	25067977	shares
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	53644314	shares
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	25067977	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.03
CY2021Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	391997	shares
CY2021Q4	prax	Sale Of Stock Consideration Received Gross Amount SaleOfStockConsiderationReceivedGrossAmount	7600000	USD
CY2021Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	7000000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10230564	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	0	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9308424	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	0	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5944546	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.47
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2018903	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	38.60
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	889974	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.75
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	19735000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	604974	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.27
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6468501	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.92
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M13D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	57146000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2001767	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.77
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y29D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	24971000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6468501	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.92
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M13D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	57146000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	700000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22693000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5211000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167061000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-61820000	USD
CY2021	prax	Temporary Equity Dividends And Accretion To Redemption Value Adjustment TemporaryEquityDividendsAndAccretionToRedemptionValueAdjustment	0	USD
CY2020	prax	Temporary Equity Dividends And Accretion To Redemption Value Adjustment TemporaryEquityDividendsAndAccretionToRedemptionValueAdjustment	8996000	USD
CY2021	prax	Gain Loss On Repurchase Of Temporary Equity GainLossOnRepurchaseOfTemporaryEquity	0	USD
CY2020	prax	Gain Loss On Repurchase Of Temporary Equity GainLossOnRepurchaseOfTemporaryEquity	493000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-167061000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-70323000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42454055	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42454055	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8950152	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8950152	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.94
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.94
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.86
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.86
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6942005	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5944546	shares
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.056
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.038
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.029
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.018
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.294
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.279
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.002
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	86916000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	37078000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	56482000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26441000	USD
CY2021Q4	prax	Deferred Tax Assets Tax Deferred Expense Amortization DeferredTaxAssetsTaxDeferredExpenseAmortization	14295000	USD
CY2020Q4	prax	Deferred Tax Assets Tax Deferred Expense Amortization DeferredTaxAssetsTaxDeferredExpenseAmortization	5774000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9296000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3053000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3759000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	170000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1952000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1433000	USD
CY2021Q4	prax	Deferred Tax Assets Operating Lease Right Of Use Asset DeferredTaxAssetsOperatingLeaseRightOfUseAsset	1132000	USD
CY2020Q4	prax	Deferred Tax Assets Operating Lease Right Of Use Asset DeferredTaxAssetsOperatingLeaseRightOfUseAsset	207000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	85957000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36873000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	959000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	205000	USD
CY2021Q4	prax	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	959000	USD
CY2020Q4	prax	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	205000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	959000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	205000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	212300000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	97100000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	7700000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	204600000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	187600000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	94500000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	86000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36900000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	49100000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	17300000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1000000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000	USD

Files In Submission

Name	View Source	Status
0001689548-22-000014-index-headers.html	Edgar Link	pending
0001689548-22-000014-index.html	Edgar Link	pending
0001689548-22-000014.txt	Edgar Link	pending
0001689548-22-000014-xbrl.zip	Edgar Link	pending
exhibit1012.htm	Edgar Link	pending
exhibit1013.htm	Edgar Link	pending
exhibit1014.htm	Edgar Link	pending
exhibit1016.htm	Edgar Link	pending
exhibit231-eyconsent.htm	Edgar Link	pending
exhibit311-peo302certifica.htm	Edgar Link	pending
exhibit312-pfo302certifica.htm	Edgar Link	pending
exhibit321-peoandpfo906cer.htm	Edgar Link	pending
exhibit43-descriptionofsec.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prax-20211231.htm	Edgar Link	pending
prax-20211231.xsd	Edgar Link	pending
prax-20211231_cal.xml	Edgar Link	unprocessable
prax-20211231_def.xml	Edgar Link	unprocessable
prax-20211231_g1.jpg	Edgar Link	pending
prax-20211231_g10.jpg	Edgar Link	pending
prax-20211231_g11.jpg	Edgar Link	pending
prax-20211231_g12.jpg	Edgar Link	pending
prax-20211231_g13.jpg	Edgar Link	pending
prax-20211231_g14.jpg	Edgar Link	pending
prax-20211231_g15.jpg	Edgar Link	pending
prax-20211231_g16.jpg	Edgar Link	pending
prax-20211231_g17.jpg	Edgar Link	pending
prax-20211231_g18.jpg	Edgar Link	pending
prax-20211231_g19.jpg	Edgar Link	pending
prax-20211231_g2.jpg	Edgar Link	pending
prax-20211231_g20.jpg	Edgar Link	pending
prax-20211231_g21.jpg	Edgar Link	pending
prax-20211231_g22.jpg	Edgar Link	pending
prax-20211231_g23.jpg	Edgar Link	pending
prax-20211231_g24.jpg	Edgar Link	pending
prax-20211231_g25.jpg	Edgar Link	pending
prax-20211231_g26.jpg	Edgar Link	pending
prax-20211231_g27.jpg	Edgar Link	pending
prax-20211231_g28.jpg	Edgar Link	pending
prax-20211231_g29.jpg	Edgar Link	pending
prax-20211231_g3.jpg	Edgar Link	pending
prax-20211231_g30.jpg	Edgar Link	pending
prax-20211231_g4.jpg	Edgar Link	pending
prax-20211231_g5.jpg	Edgar Link	pending
prax-20211231_g6.jpg	Edgar Link	pending
prax-20211231_g7.jpg	Edgar Link	pending
prax-20211231_g8.jpg	Edgar Link	pending
prax-20211231_g9.jpg	Edgar Link	pending
prax-20211231_htm.xml	Edgar Link	completed
prax-20211231_lab.xml	Edgar Link	unprocessable
prax-20211231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRAX
Praxis Precision Medicines, Inc. Stock $prax

2021 Q4 Form 10-K Financial Statement

#000168954822000014 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRAX Praxis Precision Medicines, Inc. Stock $prax

2021 Q4 Form 10-K Financial Statement

#000168954822000014 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRAX
Praxis Precision Medicines, Inc. Stock $prax